Propranolol and propranolol-LA in essential tremor: a double blind comparative study

Area of Science:

• Neurology
• Pharmacology

Background:

• Essential tremor (ET) is a common neurological disorder.
• Current treatments for ET often require multiple daily doses, impacting patient adherence.
• Developing long-acting formulations could improve ET management.

Purpose of the Study:

• To compare the efficacy of a novel long-acting propranolol formulation against conventional propranolol in reducing essential tremor amplitude.
• To identify challenges in conducting chronic pharmacological trials for essential tremor.

Main Methods:

• A double-blind, comparative study involving 15 patients with essential tremor.
• Patients received either long-acting propranolol (160, 240, or 320 mg once daily) or conventional propranolol (80 mg three times daily).
• Tremor amplitude was measured to assess efficacy.

Main Results:

• The long-acting propranolol formulation demonstrated comparable efficacy to conventional propranolol in reducing essential tremor amplitude.
• The study protocol identified inherent difficulties in the chronic pharmacological treatment trials for essential tremor.

Conclusions:

• Once-daily long-acting propranolol is a viable alternative for managing essential tremor.
• The findings provide valuable insights for designing future clinical trials in essential tremor research.